Loading...

Medigene

DB:MDG1
Snowflake Description

Excellent balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MDG1
DB
€219M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Medigene AG, a biotechnology company, develops immunotherapy platforms to treat a range of cancers in various stages. The last earnings update was 24 days ago. More info.


Add to Portfolio Compare Print
MDG1 Share Price and Events
7 Day Returns
-1.8%
DB:MDG1
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-39.4%
DB:MDG1
-10.2%
DE Biotechs
-6%
DE Market
MDG1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Medigene (MDG1) -1.8% 0.2% -2.3% -39.4% 9.1% 86.9%
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • MDG1 underperformed the Biotechs industry which returned -10.2% over the past year.
  • MDG1 underperformed the Market in Germany which returned -6% over the past year.
Price Volatility
MDG1
Industry
5yr Volatility vs Market

Value

 Is Medigene undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Medigene. This is due to cash flow or dividend data being unavailable. The share price is €8.88.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Medigene's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Medigene's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:MDG1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in EUR €-0.72
XTRA:MDG1 Share Price ** XTRA (2019-04-18) in EUR €8.92
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Medigene.

DB:MDG1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= XTRA:MDG1 Share Price ÷ EPS (both in EUR)

= 8.92 ÷ -0.72

-12.38x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Medigene is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Medigene is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Medigene's expected growth come at a high price?
Raw Data
DB:MDG1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -12.38x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
-24.1%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Medigene, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Medigene's assets?
Raw Data
DB:MDG1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in EUR €4.37
XTRA:MDG1 Share Price * XTRA (2019-04-18) in EUR €8.92
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:MDG1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= XTRA:MDG1 Share Price ÷ Book Value per Share (both in EUR)

= 8.92 ÷ 4.37

2.04x

* Primary Listing of Medigene.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Medigene is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Medigene's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Medigene has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Medigene expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-24.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Medigene expected to grow at an attractive rate?
  • Unable to compare Medigene's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Medigene's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Medigene's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:MDG1 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:MDG1 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts -24.1%
DB:MDG1 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 5.7%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:MDG1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:MDG1 Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 5 -50 -39 2
2020-12-31 18 -31 -29 4
2019-12-31 11 -24 -27 4
DB:MDG1 Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-12-31 8 -10 -17
2018-09-30 11 -15
2018-06-30 11 -11 -13
2018-03-31 10 -13
2017-12-31 8 -21 -16
2017-09-30 8 -14
2017-06-30 8 -7 -17
2017-03-31 8 -12
2016-12-31 7 -4 -9
2016-09-30 6 -8
2016-06-30 7 -14 -7
2016-03-31 7 -11

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Medigene is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Medigene's revenue is expected to grow by 5.7% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:MDG1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Medigene Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:MDG1 Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 -1.58 -1.27 -1.89 2.00
2020-12-31 -1.30 -0.91 -1.60 4.00
2019-12-31 -1.04 -0.94 -1.21 3.00
DB:MDG1 Past Financials Data
Date (Data in EUR Millions) EPS *
2018-12-31 -0.72
2018-09-30 -0.65
2018-06-30 -0.59
2018-03-31 -0.61
2017-12-31 -0.74
2017-09-30 -0.69
2017-06-30 -0.81
2017-03-31 -0.59
2016-12-31 -0.48
2016-09-30 -0.41
2016-06-30 -0.37
2016-03-31 -0.59

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Medigene will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Medigene's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Medigene has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Medigene performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Medigene's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Medigene does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Medigene's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Medigene's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Medigene's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Medigene Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:MDG1 Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 7.58 -17.05 7.62 17.12
2018-09-30 11.08 -15.05 7.91 17.08
2018-06-30 10.89 -13.35 7.34 16.11
2018-03-31 10.45 -13.45 8.05 15.58
2017-12-31 7.68 -15.99 8.27 14.88
2017-09-30 7.90 -14.46 8.67 14.63
2017-06-30 7.88 -16.56 10.36 13.90
2017-03-31 7.79 -11.78 9.58 12.76
2016-12-31 7.38 -9.49 10.03 11.54
2016-09-30 6.17 -8.17 9.75 10.30
2016-06-30 6.54 -7.29 8.16 9.49
2016-03-31 6.67 -10.71 8.20 8.99
2015-12-31 6.81 -13.00 7.62 8.53
2015-09-30 10.73 -10.67 6.96 8.33
2015-06-30 11.06 -9.03 6.66 8.21
2015-03-31 13.04 -7.39 6.62 7.83
2014-12-31 12.58 -5.76 7.09 7.50
2014-09-30 9.62 -8.20 7.58 6.87
2014-06-30 9.23 -7.47 7.85 6.57
2014-03-31 8.10 -9.05 7.93 6.45
2013-12-31 7.55 -10.28 7.54 6.61
2013-09-30 8.49 -17.43 7.81 7.35
2013-06-30 7.42 -17.75 7.67 7.21
2013-03-31 5.95 -18.03 7.98 7.31
2012-12-31 5.87 -14.88 7.92 7.40
2012-09-30 3.45 -13.70 8.23 7.38
2012-06-30 3.05 -11.21 8.40 7.49

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Medigene has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Medigene has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Medigene improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Medigene's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Medigene has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Medigene's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Medigene's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Medigene is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Medigene's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Medigene's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 41.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Medigene Company Filings, last reported 3 months ago.

DB:MDG1 Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 107.43 1.51 51.41
2018-09-30 104.95 1.43 44.33
2018-06-30 109.39 1.52 48.84
2018-03-31 82.81 1.58 49.10
2017-12-31 93.50 1.73 51.72
2017-09-30 89.06 1.21 55.37
2017-06-30 90.36 1.33 59.87
2017-03-31 74.97 0.50 48.05
2016-12-31 78.59 0.55 52.63
2016-09-30 82.05 0.60 43.60
2016-06-30 87.57 0.65 48.67
2016-03-31 88.11 0.70 46.31
2015-12-31 89.99 0.74 46.76
2015-09-30 91.77 0.79 50.77
2015-06-30 53.29 0.84 10.06
2015-03-31 45.86 0.00 13.15
2014-12-31 49.07 0.00 14.98
2014-09-30 49.43 0.00 16.69
2014-06-30 37.38 0.00 4.10
2014-03-31 37.99 0.00 7.22
2013-12-31 36.28 0.00 10.17
2013-09-30 38.87 0.00 11.66
2013-06-30 40.99 0.00 14.96
2013-03-31 41.00 0.00 16.68
2012-12-31 44.17 0.00 20.11
2012-09-30 45.53 0.00 22.24
2012-06-30 48.00 0.00 25.38
  • Medigene's level of debt (1.4%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 1.4% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Medigene has sufficient cash runway for more than 3 years based on current free cash flow.
  • Medigene has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -1.5% each year.
X
Financial health checks
We assess Medigene's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Medigene has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Medigene's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Medigene dividends.
If you bought €2,000 of Medigene shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Medigene's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Medigene's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:MDG1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:MDG1 Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Medigene has not reported any payouts.
  • Unable to verify if Medigene's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Medigene's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Medigene has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Medigene's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Medigene afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Medigene has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Medigene's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Dolores Schendel
COMPENSATION €619,000
TENURE AS CEO 3.2 years
CEO Bio

Prof. Dr. Dolores J. Schendel has been the Chief Executive Officer and Member of Executive Management Board at MediGene AG since February 1, 2016 and May 1, 2014 respectively. Prof. Dr. has been the Chief Scientific Officer at MediGene AG since February 1, 2016. Prof. Dr. Schendel serves as Director of the Institute of Molecular Immunology and Partner at Helmholtz Zentrum München, GmbH. Prof. Dr. Schendel served as Managing Director of trianta Immunotherapies GmbH and holds a professorship in immunology at the ludwig Maximilians university of Munich. Her research focuses on human immunology and immunotherapy. Prof. Dr. Schendel has served as a Member of the German Cancer aid Grants review panel and as Chair of a life Science Study panel of the european research Council.

CEO Compensation
  • Dolores's compensation has increased whilst company is loss making.
  • Dolores's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the Medigene management team in years:

5.2
Average Tenure
  • The average tenure for the Medigene management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Horst Domdey

TITLE
Co-Founder & Chairman of the Supervisory Board
COMPENSATION
€46K
AGE
67
TENURE
25.3 yrs

Dolores Schendel

TITLE
CEO, Chief Scientific Officer & Member of Executive Management Board
COMPENSATION
€619K
TENURE
3.2 yrs

Ernst-Ludwig Winnacker

TITLE
Co-Founder & Chairman Scientific Advisory Board
COMPENSATION
€20K
AGE
77

Axel-Sven Malkomes

TITLE
CFO, Chief Business Development Officer and Member of Executive Management Board

Kai Pinkernell

TITLE
Chief Medical Officer
TENURE
1 yrs

Gerard Luyben

TITLE
Vice President of Controlling & Accounting

Slavoljub Milosevic

TITLE
Head of Technology & Innovation

Julia Hofmann

TITLE
Senior Director and Head of Public & Investor Relations
TENURE
7.3 yrs
Board of Directors Tenure

Average tenure and age of the Medigene board of directors in years:

1.9
Average Tenure
63
Average Age
  • The average tenure for the Medigene board of directors is less than 3 years, this suggests a new board.
Board of Directors

Antoinette Hiebeler-Hasner

TITLE
Deputy Chairwomen of the Supervisory Board
COMPENSATION
€38K
TENURE
2.7 yrs

Horst Domdey

TITLE
Co-Founder & Chairman of the Supervisory Board
COMPENSATION
€46K
AGE
67
TENURE
5.8 yrs

Ernst-Ludwig Winnacker

TITLE
Co-Founder & Chairman Scientific Advisory Board
COMPENSATION
€20K
AGE
77
TENURE
1.7 yrs

Gerd Zettlmeissl

TITLE
Member of Supervisory Board
COMPENSATION
€18K
AGE
63
TENURE
1.9 yrs

Frank Mathias

TITLE
Member of the Supervisory Board
COMPENSATION
€146K
AGE
56
TENURE
0.9 yrs

Yi-Ta Lee

TITLE
Member of the Supervisory Board
COMPENSATION
€29K
TENURE
5.8 yrs

Keith Manchester

TITLE
Member of Supervisory Board
COMPENSATION
€15K
AGE
49
TENURE
1.9 yrs

Ron Scott

TITLE
Member of Supervisory Board
COMPENSATION
€19K
AGE
63
TENURE
1.9 yrs

Micha Drukker

TITLE
Member of Scientific Advisory Board
TENURE
1.7 yrs

Peter Krammer

TITLE
Member of Scientific Advisory Board
AGE
52
TENURE
1.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Medigene's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Medigene has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Medigene AG, a biotechnology company, develops immunotherapy platforms to treat a range of cancers in various stages. It operates through two segments, Immunotherapies and Other Products. The company develops Dendritic cell vaccines in phase I/II clinical trials; and T-cell receptor-modified T cells and T-cell-specific monoclonal antibodies in preclinical development phase. It also develops Veregen for the treatment of genital warts; and RhuDex for the treatment of autoimmune diseases. Medigene AG has strategic partnership with bluebird bio, Inc. for the development of T cell receptors; and research collaboration agreements with RXi Pharmaceuticals Corporation. The company was founded in 1994 and is headquartered in Munich, Germany.

Details
Name: Medigene AG
MDG1
Exchange: DB
Founded: 1994
€218,926,876
24,557,137
Website: http://www.medigene.com
Address: Medigene AG
Lochhamer Strasse 11,
Planegg/Martinsried,
Munich,
Bavaria, 82152,
Germany
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
XTRA MDG1 Common Stock XETRA Trading Platform DE EUR 30. Jun 2000
OTCPK MDGE.F Common Stock Pink Sheets LLC US USD 30. Jun 2000
DB MDG1 Common Stock Deutsche Boerse AG DE EUR 30. Jun 2000
LSE 0QGJ Common Stock London Stock Exchange GB EUR 30. Jun 2000
SWX MDG1 Common Stock SIX Swiss Exchange CH CHF 30. Jun 2000
WBAG MDG1 Common Stock Wiener Boerse AG AT EUR 30. Jun 2000
BATS-CHIXE MDG1D Common Stock BATS 'Chi-X Europe' GB EUR 30. Jun 2000
Number of employees
Current staff
Staff numbers
106
Medigene employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 20:38
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/11
Last earnings filing: 2019/03/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.